For the quarter ending 2026-03-31, CLDI has $9,591K in assets. $4,656K in debts.
| Balance Sheets | 2026-03-31 | 2025-09-30 | ||
|---|---|---|---|---|
| Cash | 6,631 | 10,375 | ||
| Prepaid expenses and other current assets | 722 | 653 | ||
| Total current assets | 7,353 | 11,028 | ||
| Machinery and equipment, net | 758 | 849 | ||
| Operating lease right-of-use assets, net | 1,342 | 2,012 | ||
| Other noncurrent assets | 138 | 140 | ||
| Total assets | 9,591 | 14,029 | ||
| Accounts payable-Nonrelated Party | 849 | 1,143 | ||
| Accounts payable-Related Party | 51 | 5 | ||
| Accrued expenses and other current liabilities-Nonrelated Party | 1,313 | 1,396 | ||
| Accrued expenses and other current liabilities-Related Party | 119 | 778 | ||
| Term notes payable, net of discount, including accrued interest-Related Party | - | 405 | ||
| Finance lease liability, current | 154 | 112 | ||
| Operating lease right-of-use liability, current | 1,350 | 1,354 | ||
| Total current liabilities | 3,836 | 5,193 | ||
| Operating lease right-of-use liability, noncurrent | 6 | 640 | ||
| Finance lease liability, noncurrent | 147 | 197 | ||
| Promissory note | 600 | 600 | ||
| Warrant liability | 62 | 186 | ||
| Related party warrant liability | 5 | 15 | ||
| Total liabilities | 4,656 | 6,831 | ||
| Common stock, 0.0001 par value, 330,000 shares authorized 11,787 and 7,217 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 1 | 1 | ||
| Additional paid-in capital | 150,685 | 144,495 | ||
| Accumulated other comprehensive loss, net of tax | -22 | -13 | ||
| Accumulated deficit | -145,729 | -137,565 | ||
| Total equity | 4,935 | 6,918 | ||
| Noncontrolling interest | - | 280 | ||
| Total equity | - | 7,198 | ||
| Total liabilities and total equity | 9,591 | 14,029 | ||
Calidi Biotherapeutics, Inc. (CLDI)
Calidi Biotherapeutics, Inc. (CLDI)